Arthritis News and Research

Latest Arthritis News and Research

Final results from Vertex VX-509 Phase 2a study on RA

Vertex Pharmaceuticals Incorporated today announced the final results from a Phase 2a study of the investigational selective oral JAK3 inhibitor VX-509.

6 Nov 2011

Patients with RA have lower expectations about postsurgical outcomes after TKA

Compared with osteoarthritis patients, individuals with rheumatoid arthritis who undergo total knee replacement surgery have lower expectations about their postsurgical outcomes, according to a new study by researchers at Hospital for Special Surgery (HSS) in New York City.

6 Nov 2011

$Women under 50 with RA more likely to have new fractures$

Women under 50 with RA more likely to have new fractures

Women under 50 with rheumatoid arthritis are at greater risk of breaking bones than women without the condition, according to a Mayo Clinic study being presented at the American College of Rheumatology annual scientific meeting in Chicago.

6 Nov 2011

APF launches new online educational module on safe use of CAM

The American Pain Foundation (APF) announced the launch of a new online educational module focusing on safe use of complementary and alternative medicine (CAM) as part of its PainSAFE initiative.

5 Nov 2011

Dark, cold weather derails physical activity routines of older people with arthritis: Study

As cold winter weather sets in and daylight hours dwindle, many older Chicagoans with arthritis tend to sit idle, missing out on the daily dose of physical activity they need to improve their health, according to a Northwestern Medicine study.

5 Nov 2011

SCRIP honors Glenmark for business excellence and innovative R & D capabilities

SCRIP, a leading global pharmaceutical and biotech news publication, honoured Glenmark with two global recognitions, for its business excellence and innovative R & D capabilities.

5 Nov 2011

Vertex announces 16 grant recipients of Hep-C Circle of Care program

Vertex Pharmaceuticals Incorporated today announced that it has awarded 16 grants totaling approximately $1.5 million to a variety of academic, patient and community groups as part of the Vertex Hep-C Circle of Care program, a pilot competitive grants program designed to foster innovative approaches to patient care and support people living with chronic hepatitis C.

5 Nov 2011

Positive data from RegeneRx RGN-259 Phase 2 trial on dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. today announced positive data from its 72-patient, Phase 2 clinical trial with RGN-259, a sterile, preservative-free eye drop, to evaluate its safety and efficacy for the treatment of signs and symptoms of dry eye syndrome over a treatment period of 30 days using the Controlled Adverse Environment (CAE) model.

5 Nov 2011

Osiris Therapeutics third quarter revenues decrease marginally to $10.6 million

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory and cardiovascular disease areas and wound healing, announced today its results for the third quarter ended September 30, 2011.

4 Nov 2011

Women and men ages 45 to 64 more likely to be hospitalized for knee replacement surgery

Women and men ages 45 to 64 were 2.5 times more likely to be hospitalized for knee replacement surgery in 2009 than in 1997, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

4 Nov 2011

Quintiles receives two awards for clinical research

Quintiles' digital efforts to bridge the gaps between clinical research, patients and clinical trial participants have been recognized in the form of two International Davey Awards and a Web Health Award this week.

4 Nov 2011

Final results from Vertex KALYDECO second of two Phase 3 studies on CF

Vertex Pharmaceuticals Incorporated today announced final results from the ENVISION study, the second of two pivotal Phase 3 studies of KALYDECO, a medicine in development that targets the defective protein that causes cystic fibrosis.

4 Nov 2011

POZEN third quarter revenue increases to $4.9 million

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the third quarter ended September 30, 2011.

3 Nov 2011

BUSM researcher receives two NIH grants to study scleroderma

Boston University School of Medicine (BUSM) researcher Robert Lafyatis, MD, recently was awarded two grants from the National Institutes of Health's (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases.

3 Nov 2011

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Abbott scientists and independent researchers will highlight the latest research findings on HUMIRA (adalimumab) at this year's American College of Rheumatology (ACR) Annual Scientific Meeting, scheduled for November 5-9 in Chicago.

3 Nov 2011

Zalicus third quarter revenue increases to $2.4 million

Zalicus Inc. today reported financial results for the third quarter ended September 30, 2011.

2 Nov 2011

Glyphosine can prevent development of type 1 diabetes

Researchers at the University of Colorado School of Medicine have found a specific molecule that can prevent the development of type 1 diabetes in mice and has a similar effect on human cells from diabetic patients.

2 Nov 2011

Regular Yoga eases chronic back pain: Study

A new study found that those with chronic back pain might benefit from regular yoga. Three months of weekly yoga classes eased back pain more than the usual course of care — an informative back pain booklet said researchers. Even a year later, patients with chronic back pain who had participated in yoga classes reported less pain than those who hadn't been assigned the classes.

1 Nov 2011

Rigel reports net loss of $17.9 million for third quarter 2011

Rigel Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2011.

1 Nov 2011

Scientists identify genetic mutation that causes rare childhood disease

An international collaboration of scientists, including researchers at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health, has identified a genetic mutation that causes a rare childhood disease characterized predominantly by inflammation and fat loss.

1 Nov 2011